MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- ALEMBIC - TEVA PHARMA (Israel)
ALEMBIC vs TEVA PHARMA (Israel) - Comparison Results
ALEMBIC Change
Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 ALEMBIC  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ALEMBIC Mar-18 |
TEVA PHARMA Dec-13 |
ALEMBIC/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 72 | 3,117 | - | |
| Low | Rs | 34 | 2,708 | - | |
| Sales per share (Unadj.) | Rs | 4.7 | 1,788.7 | - | |
| Earnings per share (Unadj.) | Rs | 6.1 | 111.7 | - | |
| Cash flow per share (Unadj.) | Rs | 6.2 | 256.3 | - | |
| Dividends per share (Unadj.) | Rs | 0.20 | 97.82 | - | |
| Dividend yield (eoy) | % | 0.4 | 3.4 | 11.2% | |
| Book value per share (Unadj.) | Rs | 40.7 | 1,986.9 | - | |
| Shares outstanding (eoy) | m | 267.03 | 848.00 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 11.3 | 1.6 | 691.9% | |
| Avg P/E ratio | x | 8.7 | 26.1 | 33.3% | |
| P/CF ratio (eoy) | x | 8.5 | 11.4 | 74.6% | |
| Price / Book Value ratio | x | 1.3 | 1.5 | 88.9% | |
| Dividend payout | % | 3.3 | 87.5 | 3.7% | |
| Avg Mkt Cap | Rs m | 14,139 | 2,469,486 | 0.6% | |
| No. of employees | `000 | NA | 44.9 | 0.0% | |
| Total wages/salary | Rs m | 207 | 0 | - | |
| Avg. sales/employee | Rs Th | NM | 33,748.9 | - | |
| Avg. wages/employee | Rs Th | NM | 0 | - | |
| Avg. net profit/employee | Rs Th | NM | 2,108.3 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 1,255 | 1,516,846 | 0.1% | |
| Other income | Rs m | 370 | 0 | - | |
| Total revenues | Rs m | 1,625 | 1,516,846 | 0.1% | |
| Gross profit | Rs m | 111 | 415,389 | 0.0% | |
| Depreciation | Rs m | 38 | 122,608 | 0.0% | |
| Interest | Rs m | 2 | 29,793 | 0.0% | |
| Profit before tax | Rs m | 442 | 262,988 | 0.2% | |
| Minority Interest | Rs m | 0 | 1,195 | 0.0% | |
| Prior Period Items | Rs m | 1,212 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -172,637 | 0.0% | |
| Tax | Rs m | 24 | -3,211 | -0.7% | |
| Profit after tax | Rs m | 1,630 | 94,756 | 1.7% | |
| Gross profit margin | % | 8.9 | 27.4 | 32.3% | |
| Effective tax rate | % | 5.4 | -1.2 | -444.0% | |
| Net profit margin | % | 129.8 | 6.2 | 2,078.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 1,867 | 1,024,472 | 0.2% | |
| Current liabilities | Rs m | 591 | 893,427 | 0.1% | |
| Net working cap to sales | % | 101.6 | 8.6 | 1,176.6% | |
| Current ratio | x | 3.2 | 1.1 | 275.4% | |
| Inventory Days | Days | 94 | 91 | 103.8% | |
| Debtors Days | Days | 74 | 96 | 76.7% | |
| Net fixed assets | Rs m | 1,791 | 495,435 | 0.4% | |
| Share capital | Rs m | 534 | 3,734 | 14.3% | |
| Net worth | Rs m | 10,858 | 1,684,929 | 0.6% | |
| Long term debt | Rs m | 41 | 775,597 | 0.0% | |
| Total assets | Rs m | 11,591 | 3,466,480 | 0.3% | |
| Interest coverage | x | 260.9 | 9.8 | 2,654.7% | |
| Debt to equity ratio | x | 0 | 0.5 | 0.8% | |
| Sales to assets ratio | x | 0.1 | 0.4 | 24.7% | |
| Return on assets | % | 14.1 | 3.6 | 391.8% | |
| Return on equity | % | 15.0 | 5.6 | 266.9% | |
| Return on capital | % | 15.2 | 4.9 | 308.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 236 | 241,707 | 0.1% | |
| From Investments | Rs m | -224 | -85,646 | 0.3% | |
| From Financial Activity | Rs m | -27 | -289,944 | 0.0% | |
| Net Cashflow | Rs m | -15 | -133,883 | 0.0% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 74.67 Rs / USD
Compare ALEMBIC With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare ALEMBIC With: VENUS REMEDIES DR. REDDYS LAB PIRAMAL ENTERPRISES SUVEN LIFE SCIENCES ALKEM LABORATORIES
Today's Market
Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
Related Views On News
ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)
Aug 10, 2020 | Updated on Aug 10, 2020For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)
Aug 27, 2019 | Updated on Aug 27, 2019For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
More Views on NewsMost Popular
A Critical Update on the Market (Fast Profits Daily)
Mar 30, 2021In this video, I'll tell you why I am recommending caution in the market at this time.
My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)
Mar 31, 2021A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
My Stock Trading Strategy (Fast Profits Daily)
Mar 31, 2021In this video I'll show you exactly how I go about picking stocks for trading.
What You Need to Find Hundred Baggers (Profit Hunter)
Mar 30, 2021100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More
